EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors

Journal:
Proceedings of the National Academy of Sciences of the United States of America
Published:
DOI:
10.1073/pnas.2510829122
Affiliations:
5
Authors:
25
Go to article
Institutions Authors Share
EvolveImmune Therapeutics, United States of America (USA)
22.000000
22.000000
22.000000
 0.88
non-affiliated author contributions, United States of America (USA)
1.000000
 0.04
Salk Institute for Biological Studies (Salk), United States of America (USA)
1.000000
 0.04
Regeneron Pharmaceuticals, United States of America (USA)
0.500000
 0.02
Fred Hutchinson Cancer Center, United States of America (USA)
0.500000
 0.02
Interested in Oncology and Carcinogenesis?